Cipla receives regulatory approval for launch of Ciplenza in India to treat mild to moderate COVID-19 Kumar Jeetendra | July 24, 2020 Mumbai, India; July 24, 2020: Cipla Limited (BSE: 500087; NSE: CIPLA EQ, hereinafter referred to as “Cipla”), today announced that it has been granted regulatory approval by the Drug Controller General of India (DCGI) for the launch of Favipiravir in the country under the brand name Ciplenza. The accelerated approval for manufacturing and marketing of …
Lupin dispatches COVID-19 medication Favipiravir in India at Rs 49 for each tablet Kumar Jeetendra | August 5, 2020 Drug major Lupin on Wednesday announced the launch of its Favipiravir medication under the brand name’Covihalt’ for its treatment patients with mild to moderate COVID-19 symptoms at Rs 49 per pill in India. Favipiravir has received authorisation from the Drug Controller General of India (DCGI) for emergency use, Lupin said in a regulatory filing. Its …
